French Scientist with Parkinson’s Develops Potential Breakthrough Drug

Guillaume Brachet, a 35-year-old Frenchman living near Tours, is redefining what it means to live with Parkinson’s disease. Diagnosed with young-onset Parkinson’s at just 29, Guillaume is now working tirelessly to develop a groundbreaking treatment for the condition. With a PhD in biology and a professional background as a pharmacist, medical biologist, and assistant lecturer, Guillaume has drawn on his expertise and determination to pursue a potential disease-modifying therapy. Turning Knowledge into Hope Guillaume’s journey began with a deep dive into scientific literature. After reading over 700 articles on Parkinson’s, he developed a theory: combining specific existing medications could potentially slow the progression of the disease. Despite his innovative idea, pharmaceutical companies initially pushed back, requesting more research to validate his hypothesis. Determined, Guillaume decided to take matters into his own hands. In 2022, he launched the Parkinson sur Loire challenge, kayaking 150 kilometers upstream along the Loire River to symbolize his fight against Parkinson’s. The challenge raised €45,000, which two research organizations, Neuron Experts and Syncrosome, matched to fund laboratory research. From Theory to Reality By April 2023, the lab results were promising, spurring Guillaume to found CXS Therapeutics, a company focused on drug development. A subsidiary, Sappiens, was also established to concentrate on his patented drug candidate, CXS003. The treatment, which Guillaume hopes will slow the progression of Parkinson’s, is moving towards phase 2 trials in 2025. If successful, the drug could be available by 2029. Balancing Ambition with Reality As CEO of both companies, Guillaume works 70 hours a week, balancing hope and practicality. His efforts are not only driven by scientific curiosity but also by a personal commitment to improving the lives of people with Parkinson’s. “I was looking for hope,” he shares. “I wanted to see if a new treatment could happen in my lifetime.” A Future of Possibility Guillaume’s story is a testament to resilience and innovation, showcasing how personal adversity can inspire groundbreaking efforts. His work, fueled by determination and community support, holds promise for millions living with Parkinson’s worldwide.